A Randomized, Double-Blind, Non-Inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects With or Without Gout

ConclusionsUsing a novel dose-titration method, although the primary endpoint of non-inferiority of febuxostat 40  mg/day versus allopurinol 300 mg/day was not reached, non-inferiority and superiority of febuxostat 60 mg/day and 80 mg/day versus allopurinol 300 mg/day was demonstrated at weeks 16 and 24, respectively. Febuxostat demonstrated an acceptable tolerability profile in the treatment of hyperurice mia in Chinese subjects with or without gout.Trial RegistrationJapicCTI-132106.FundingAstellas Pharma Global Development, Inc.

Source: Rheumatology and Therapy - September 16, 2019 Category: Rheumatology Source Type: research